surmount-1 tirzepatide weight loss percent nejm 2022 for the Treatment of Obstructive Sleep Apnea and Obesity SURPASS-2 (NEJM 2021) was the
Description
As a GIP receptor agonist, tirzepatide enhances insulin secretion and may potentially improve insulin sensitivity while reducing glucagon secretion, though these mechanisms continue to be studied
It uses the same molecule at a lower dose
NLM Identifier: NCT06962280
For diabetes management, regular monitoring of HbA1c (every 3 months initially) and body weight helps assess treatment efficacy and guide dose adjustments
Nausea more than doubles
Earn Earn Credits Earn 1 performance credit per $1 spent on labs and protocols
